Final analysis of the investigator-initiated randomized study of anti–PD-L1 durvalumab (durva) with radiation versus chemoradiation (CRT) for intermediate-risk HPV-positive (HPV+) locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC): Canadian Cancer Trials Group (CCTG) HN.9 (EORTC 1740-HNCG).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Anna Spreafico, Khalil Sultanem, Jean-Pascal H. Machiels, Scott Victor Bratman, John Hilton, Lisa F. L. Licitra, Alexander V. Louie, Andrea McNiven, Jolie Ringash, Lillian L. Siu, John Waldron, Osama Souied, Andrew George Robinson, Changshu Wang, Craig Henry Harlos, Marc Oliva, John WT Walker, Kate Whelan, Wei Tu, Wendy R. Parulekar
Institutions: University Health Network, University of Toronto, Princess Margaret Cancer Centre, Jewish General Hospital, UCLouvain, Ottawa Hospital, Fondazione IRCCS Istituto Nazionale dei Tumori, Sunnybrook Health Science Centre, Arthur J.E. Child Comprehensive Cancer Centre, Cancer Care Alberta, University of Saskatchewan, Kingston General Hospital, Université de Sherbrooke, CancerCare Manitoba, University of Manitoba, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, University of Alberta, Cross Cancer Institute, Canadian Cancer Trials Group, Queen's University
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162527110